Advertisement

Picture EBD Group BIO-Europe Spring 2021 Digital 650x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 1969 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Evox Therapeutics–Alphabet: investment, 202102 financing round Series C totalling £69.2m incl existing + co-investor GV 2021-02-18
Evox Therapeutics–Cowen: investment, 202102 financing round Series C totalling £69.2m incl existing + co-investor Cowen Healthcare Investments 2021-02-18
Evox Therapeutics–Invus Group: investment, 202102 financing round Series C totalling £69.2m incl new + co-investor Invus 2021-02-18
Evox Therapeutics–Lilly: investment, 202102 financing round Series C totalling £69.2m incl new + co-investor Lilly converting $10m bond 2021-02-18
Evox Therapeutics–OrbiMed: investment, 202102 financing round Series C totalling £69.2m incl new + co-investor OrbiMed 2021-02-18
Evox Therapeutics–Panacea Venture: investment, 202102 financing round Series C totalling £69.2m incl existing + co-investor Panacea Venture 2021-02-18
Evox Therapeutics–Redmile Group: investment, 202102 financing round Series C totalling £69.2m incl exisiting + lead investor Redmile Group 2021-02-18
Evox Therapeutics–SEVERAL: investment, 202102 financing round Series C £69.2m led by Redmile Group plus OrbiMed + Invus + all Series B investors 2021-02-18
Evox Therapeutics–Univ Oxford: investment, 202102 financing round Series C totalling £69.2m incl existing + co-investor OSI 2021-02-18
Cognate BioServices–Charles River: investment, 202102– acquisition $875m in cash by Charles River ANNOUNCED 2021-02-17
SpyBiotech–Alphabet: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor GV 2021-02-10
SpyBiotech–Braavos Investment Advisors: investment, 202102 financing round Series A totalling $32.5m incl new + lead investor Braavos 2021-02-10
SpyBiotech–Oxford Investment Consultants: investment, 202102 financing round Series A totalling $32.5m incl new + co-investor OIC 2021-02-10
SpyBiotech–SEVERAL: investment, 202102 financing round Series A $32.5m led by new investor Braavos Investment Advisers 2021-02-10
SpyBiotech–United Kigdom (govt): investment, 202102 financing round Series A totalling $32.5m incl Future Fund converting prior convertible loan 2021-02-10
SpyBiotech–Univ Oxford: investment, 202102 financing round Series A totalling $32.5m incl existing + co-investor Oxford Sciences Innovation 2021-02-10
PepGen–Verge Scientific Communications: public relations, 202102 service existent by Verge 2021-02-04
Abingworth–Huntsworth: public relations, 202102 service existent by Citigate Dewe Rogerson 2021-02-03
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund 2021-02-03
GW Pharmaceuticals–Jazz Pharmaceuticals: investment, 202102– acquisition $7.2b at $220/ADS with $200 in cash + $20 in ordinary shares ANNOUNCED 2021-02-03
Avacta–Adeptrix: MS-based SARS-CoV-2 test, 202101 collab existent developm of BAMS SARS-CoV-2 assay for research + IVD 2021-01-28
Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test 2021-01-28
Minoryx–Image Box: public relations, 202101 service existent by Image Box Communications 2021-01-26
Lift BioSciences–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital 2021-01-25
Neurent Medical–Atlantic Bridge: investment, 202101 financing round Series B totalling €21m incl co-lead investor Atlantic Brdige Growth Fund IV 2021-01-20
Neurent Medical–Fountain Healthcare Partners: investment, 202101 financing round Series B totalling €21m incl existing + co-investor Fountain HP 2021-01-20
Neurent Medical–Life Sciences Partners: investment, 202101 financing round Series B totalling €21m incl lead investor LSP Health Economics Fund 2 2021-01-20
Neurent Medical–SEVERAL: investment, 202101 financing round Series B €21m led by LSP Health Economics Fund 2 2021-01-20
ConserV Bioscience–Optimum Strategic Communications: public relations, 202101 service existent by Optimum 2021-01-19
ConserV Bioscience–United States (govt): coronavirus vaccine, 202101– collab developm broad spectrum coronvirus vaccine using NLP technology from LLNL 2021-01-19
Slate Bio–Epidarex Capital: investment, 202101 seed financing round totalling $1.75m incl lead investor Epidarex Capital 2021-01-19
Slate Bio–SEVERAL: investment, 202101 seed financing round $1.75m led by Epidarex Capital 2021-01-19
Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors 2021-01-13
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based 2021-01-11
Immunocore–BlackRock: investment, 202101 financing round Series C totalling $75m incl funds + accounts managed by BlackRock 2021-01-11
Immunocore–SEVERAL: investment, 202101 financing round Series C $75m incl funds + accounts managed by BlackRock 2021-01-11
Immunocore–Wafra: credit, 202101– senior secured loan facility $100m from Oxford Finance LLC 2021-01-11
Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED 2021-01-11
Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP 2021-01-11
BioGeneration Ventures–Instinctif Partners: public relations, 202101 service existent by Instinctif 2021-01-07
BioGeneration Ventures–Schroders: investment, 202101 final closing of BGV IV totalling €140m incl investor Schroder Adveq 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
Oxford Immunotec–PerkinElmer: investment, 202101– acquisition $591m with $22/share in cash ANNOUNCED 2021-01-07
Clinigen–Instinctif Partners: public relations, 202101 service existent by Instinctif 2021-01-04
Faron Pharmaceuticals–Precision Medicine Group: public relations, 202101 service existent IR by Stern IR 2021-01-04
Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use 2021-01-01
SomaLogic–Janus Henderson: investment, 202012 financing round Series A 2nd closing totalling addit $81m incl Janus Henderson Investors 2020-12-22
SomaLogic–Redmile Group: investment, 202012 financing round Series A 2nd closing totalling addit $81m incl Redmile Group 2020-12-22
SomaLogic–SEVERAL: investment, 202012 financing round Series A 2nd closing additional $81m bringing total Series A to $204m or $214m 2020-12-22
Peptilogics–Angermayer Group: investment, 202012 financing round Series B totalling $35.4m incl new + lead investor Presight Capital 2020-12-21
Peptilogics–SEVERAL: investment, 202012 financing round Series B $35.4m led by Presight Capital 2020-12-21
InnoSkel–Consilium: public relations, 202012 service existent by Consilium Strategic Communications 2020-12-14
Alexion–AstraZeneca: investment, 202012– acquisition $39b with $13.4b in cash + $25.6b in ADSs Alexion shareholders will own 15% of combined firm 2020-12-12
NanoSyrinx–Sciad Communications: public relations, 202012 service existent by Sciad 2020-12-10
PepGen–CureDuchenne: investment, 202012 financing round Series A totalling $45m incl co-investor CureDuchenne Ventures 2020-12-09
PepGen–RA Capital: investment, 202012 financing round Series A totalling $45m incl lead investor RA Capital Management 2020-12-09
PepGen–SEVERAL: investment, 202012 financing round Series A $45m led by RA Capital Management 2020-12-09
PepGen–Univ Oxford: investment, 202012 financing round Series A totalling $45m incl co-investor University of Oxford 2020-12-09
PepGen–Univ Oxford: investment, 202012 financing round Series A totalling $45m incl existing + co-investor Oxford Sciences Innovation 2020-12-09
RetinAI Medical–Charles Consultants: public relations, 202012 service existent by Sue Charles 2020-12-08
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
BioNTech–InstaDeep: AI-based drug discovery, 2019– collab initiated in 2019 2020-11-25
BioNTech–InstaDeep: AI-based drug discovery, 202011– strategic collab incl joined AI Innovation Lab to develop immunotherapies 2020-11-25
Catamaran Bio–SEVERAL: investment, 202011 financing round Series A $42m co-led by Sofinnova Partners + Lightstone Ventures 2020-11-23
Catamaran Bio–SV Health Investors: investment, 202011 financing round Series A $42m incl existing founding + co-investor SV Health Investors 2020-11-23
Omnix Medical–SEVERAL: investment, 202011 financing round $8.5m co-led by Tal Capital + Entrée Capital + CBG Group 2020-11-20
Achilles Therapeutics–Consilium: public relations, 202011 service existent by Consilium Strategic Communications 2020-11-19
Achilles Therapeutics–Forbion: investment, 202011 financing round Series C totalling £52.7m incl existing investor Forbion 2020-11-19
Achilles Therapeutics–Invus Group: investment, 202011 financing round Series C totalling £52.7m incl existing investor Invus 2020-11-19
Achilles Therapeutics–OrbiMed: investment, 202011 financing round Series C totalling £52.7m incl new investor OrbiMed 2020-11-19
Achilles Therapeutics–Perceptive Advisors: investment, 202011 financing round Series C totalling £52.7m incl existing investor Perceptive Advisors 2020-11-19
Achilles Therapeutics–PNC Financial Services: public relations, 202011 service existent US investor relations by Solebury Trout 2020-11-19
Achilles Therapeutics–RA Capital: investment, 202011 financing round Series C totalling £52.7m incl existing investor RA Capital Management 2020-11-19
Achilles Therapeutics–Redmile Group: investment, 202011 financing round Series C totalling £52.7m incl existing investor Redmile Group 2020-11-19
Achilles Therapeutics–SEVERAL: investment, 202011 financing round Series C £52.7m with new + existing investors 2020-11-19
Achilles Therapeutics–Syncona: investment, 202011 financing round Series C totalling £52.7m incl existing investor Syncona 2020-11-19
Achilles Therapeutics–Tavistock: investment, 202011 financing round Series C totalling £52.7m incl new investor Boxer Capital 2020-11-19
SynOx Therapeutics–Forbion: investment, 202011 financing round Series A totalling €37m incl co-investor Forbion 2020-11-19
SynOx Therapeutics–Gimv: investment, 202011 financing round Series A totalling €37m incl co-investor Gimv 2020-11-19
SynOx Therapeutics–Medicxi: investment, 202011 financing round Series A totalling €37m incl co-lead investor Medicxi 2020-11-19
SynOx Therapeutics–Odlander Fredrikson: investment, 202011 financing round Series A totalling €37m incl co-lead investor HealthCap 2020-11-19
SynOx Therapeutics–Roche: emactuzumab, 202011 excl ww rights for developm + production + commercialisation 2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
Emergex–Consilium: public relations, 202011 service existent by Consilium Strategic Communications 2020-11-18
Emergex–SEVERAL: investment, 202011 financing round $11m from new + existing investors 2020-11-18
Myricx Pharma–Brandon Capital: investment, 202011 seed financing round totalling £4.5m incl investor Brandon Capital Partners 2020-11-16
Myricx Pharma–SEVERAL: investment, 202011 seed financing round £4.5m with Sofinnova Partners + Brandon Capital Partners 2020-11-16
Myricx Pharma–Sofinnova: investment, 202011 seed financing round totalling £4.5m incl investor Sofinnova Partners 2020-11-16
Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV 2020-11-12
Apeiron–Domainex: drug discovery services, 202011– collab expansion supply of lead optimisation services for Cbl-b targeting APN431 compound series 2020-11-09
Congenica–Cambridge Innovation Capital: investment, 202011 financing round Series C totalling £39m incl existing + co-investor CIC 2020-11-09
Congenica–Consilium: public relations, 202011 service existent by Consilium Strategic Communications 2020-11-09
Congenica–Downing Ventures: investment, 202011 financing round Series C totalling £39m incl existing + co-investor Downing 2020-11-09
Congenica–IDO Investments: investment, 202011 financing round Series C totalling £39m incl new + co-investor IDO Investments 2020-11-09
Congenica–Lazard: financial services, 202011 supply service Lazard is financial advisor with regard to £39m Series C financing round 2020-11-09
Congenica–Legal & General: investment, 202011 financing round Series C totalling £39m incl new + co-lead investor Legal & General 2020-11-09
Congenica–Parkwalk Advisors: investment, 202011 financing round Series C totalling £39m incl existing + co-investor Parkwalk 2020-11-09
Congenica–Puhua Capital: investment, 202011 financing round Series C totalling £39m incl new + co-investor Puhua Capital 2020-11-09
Congenica–SEVERAL: investment, 202011 financing round Series C £39m ($50m) co-led by Tencent + Legal & General 2020-11-09
Congenica–Tencent: investment, 202011 financing round Series C totalling £39m incl new + co-lead investor Tencent 2020-11-09
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page



Advertisement

Picture [iito] Plain Stupid Simple 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top